Abstract
Patients with moderate-to-severe psoriasis, will require phototherapy, systemic therapy, or both for adequate disease control. Although a number of well established therapies are available for psoriasis, there are still unmet needs remain, such as longterm safety and practicability. Psoriasis currently regarded as an immune-mediated inflammatory disease, inflammatory response is amplified as a result of increased tumor necrosis factor (TNF) α expression in psoriatic plaques. New biological agents targeting TNFα are promising in psoriasis therapy. Adalimumab is an fully human recombinant IgG 1 monoclonal antibody specific for human TNF α that has been approved for the treatment of rheumatoid arthritis. Adalimumab has only recently been introduced to dermatology. Given the known pathophysiologic role of TNF in psoriasis, this brief review aimed to evaluate the efficacy and safety of adalimumab in the treatment of psoriasis and other dermatoses which it found off-label uses.
Keywords: Adalimumab, psoriasis, biological agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Adalimumab
Volume: 6 Issue: 3
Author(s): Meltem Uslu
Affiliation:
Keywords: Adalimumab, psoriasis, biological agents
Abstract: Patients with moderate-to-severe psoriasis, will require phototherapy, systemic therapy, or both for adequate disease control. Although a number of well established therapies are available for psoriasis, there are still unmet needs remain, such as longterm safety and practicability. Psoriasis currently regarded as an immune-mediated inflammatory disease, inflammatory response is amplified as a result of increased tumor necrosis factor (TNF) α expression in psoriatic plaques. New biological agents targeting TNFα are promising in psoriasis therapy. Adalimumab is an fully human recombinant IgG 1 monoclonal antibody specific for human TNF α that has been approved for the treatment of rheumatoid arthritis. Adalimumab has only recently been introduced to dermatology. Given the known pathophysiologic role of TNF in psoriasis, this brief review aimed to evaluate the efficacy and safety of adalimumab in the treatment of psoriasis and other dermatoses which it found off-label uses.
Export Options
About this article
Cite this article as:
Meltem Uslu , Adalimumab, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2007; 6 (3) . https://dx.doi.org/10.2174/187152307781368210
DOI https://dx.doi.org/10.2174/187152307781368210 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Introduction from Editor-in-Chief
Current Rheumatology Reviews Stress, Depression and Antidepressant Treatment Options in Patients Suffering from Multiple Sclerosis
Current Pharmaceutical Design Calcium Metabolism and Oxidative Stress in Bone Fractures: Role of Antioxidants
Current Drug Metabolism Bioactive Peptides from Marine Sources as Potential Anti-Inflammatory Therapeutics
Current Protein & Peptide Science Withdrawal Notice: Therapeutic Options for Treatment of COVID-19: A Review from Repurposed Drugs to New Drug Targets
Current Drug Targets TNF-α Polymorphisms and Maternal Depression in a Mexican Mestizo Population
CNS & Neurological Disorders - Drug Targets The Use of n-3 Polyunsaturated Fatty Acids as Therapeutic Agents for Inflammatory Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Current Therapy in Sarcoidosis, the Role of Existing Drugs and Future Medicine
Inflammation & Allergy - Drug Targets (Discontinued) Extrahepatic Targets and Cellular Reactivity of Drug Metabolites
Current Medicinal Chemistry Nitric Oxide Signaling and the Cross Talk with Prostanoids Pathways in Vascular System
Medicinal Chemistry Therapeutic Targeting of Leukocyte Trafficking Across the Blood-Brain Barrier
Inflammation & Allergy - Drug Targets (Discontinued) Tumor Necrosis Factor Blocking Therapy and Congestive Heart Failure in Patients with Inflammatory Rheumatic Disorders: A Systematic Review
Current Medicinal Chemistry Transferrin and the Transferrin Receptor: Of Magic Bullets and Other Concerns
Inflammation & Allergy - Drug Targets (Discontinued) Vulnerable Plaque and Inflammation: Potential Clinical Strategies
Current Pharmaceutical Design Challenging the Current Approaches to Multiple Myeloma-Related Bone Disease: From Bisphosphonates to Target Therapy
Current Cancer Drug Targets Rheumatoid Foot and Ankle Surgery
Current Rheumatology Reviews Microbial Agents – Parasites
Current Rheumatology Reviews Withdrawal Notice: Electro-Catalytic process for the Synthesis of Organic Compounds and their Biological Applications
Current Organic Synthesis The Relevance of IgE in the Pathogenesis of Allergy: The Effect of an Anti-IgE Drug in Asthma and Other Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Utility and Limitations of SP600125, an Inhibitor of Stress-Responsive c-Jun N-Terminal Kinase
Current Enzyme Inhibition